Filing Flows › Ovid Therapeutics (OVID) › Q3 2025
Ovid Therapeutics (OVID) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Ovid Therapeutics (OVID) reported revenue of $132K for the third quarter 2025 (Q3 2025), -24% from a year earlier and -98% from the quarter before.
Ovid Therapeutics, Q3 2025: revenue $132K (-24% year over year), net loss $12.2M, operating cash flow −$12.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $132K | -98% | -24% |
| Operating profit | −$12.5M | — | — |
| Net earnings | −$12.2M | — | — |
| Operating cash flow | −$12.9M | — | — |
What changed
Revenue was $132K in Q3 2025, down 24% year over year and down 98% from the previous quarter.
Operating costs exceeded revenue by $12.5M, an operating margin of -9487.1%. Total costs fell 6% while revenue fell 24%. The fastest-growing cost line was General & admin (+22%). The quarter ended with a net loss of $12.2M, wider than the previous quarter's $4.7M loss.
Operating cash flow was −$12.9M. Non-cash charges added back $16K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $1.8M.
Questions
What was Ovid Therapeutics' revenue in the third quarter 2025?
Ovid Therapeutics (OVID) reported revenue of $132K for the third quarter 2025 (Q3 2025), -24% from a year earlier and -98% from the quarter before.
Source: Ovid Therapeutics 10-Q on SEC EDGAR.